Advent International has agreed to acquire PatientPoint, the largest digital point-of-care engagement network in the United States, from a shareholder group led by L Catterton and Littlejohn & Co.

PatientPoint, with more than 35 years of experience, connects patients, providers, and healthcare brands through a nationwide network spanning 30,000 physician offices and 125,000 providers. Its platform delivers targeted, behaviour-changing content and diagnostic tools at critical moments of care, enabling pharmaceutical and health sponsors to run measurable and efficient engagement campaigns.

“We’re excited to help the company provide increasingly targeted messaging about treatment options and advanced therapies, offering sponsors and partners more efficient, personalised, and measurable campaigns,” said Chris Comenos, Director at Advent. 

Carmine Petrone, Managing Director at Advent, added: “Drawing on Advent’s deep experience scaling innovative healthcare and pharmaceutical services companies, we look forward to working closely with CEO Sean Slovenski and the PatientPoint team to accelerate the company’s network expansion and drive product innovation.”

Slovenski welcomed the investment, noting that Advent’s backing will enable PatientPoint to “accelerate growth, expand our network, and continue to deliver measurable value for providers, patients, and health brands.” Chief Commercial Officer Linda Ruschau said the deal represents a “catalyst for growth” that will allow the company to innovate faster and expand its reach.

PatientPoint’s existing management team will continue to lead the company, supported by Advent’s healthcare and digital expertise.

The transaction is expected to close in Q4 2025, subject to regulatory approvals. Advisors included Jefferies and Citi (financial) and Gibson Dunn & Crutcher (legal) for PatientPoint, while Advent was advised by Solomon Partners (financial) and Ropes & Gray (legal).

If you think we missed any important news, please do not hesitate to contact us at [email protected].

Can`t stop reading? Read more.